{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:59:59Z","timestamp":1792191599904,"version":"4.4.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The term heparin resistance is likely best defined as the failure of an appropriate dose of unfractionated heparin (UFH) to achieve a predetermined level of anticoagulation. Unfortunately, and despite many prior reports, there is no established consensus as to what either the appropriate dose or the predetermined level should be. Traditionally, assays used to monitor anticoagulation with UFH have been clot based, including the activated partial thromboplastin time, used for patients on the ward or intensive care unit, and the activated clotting time, used for patients undergoing vascular interventions and cardiopulmonary bypass. Unfortunately, these tests may be highly influenced by other factors occurring in many patients, especially those with inflammation or acute infection, as noted during the COVID-19 pandemic. Many hospitals have thus moved to anti-Xa testing for heparin monitoring. Another important factor in defining heparin resistance includes dosing, whether weight-based or total daily dosing is used, as initial reports of heparin resistance described daily doses independent of body weight. Multiple causes of apparent heparin resistance include hypercoagulability, antithrombin deficiency, andexanet alfa used for direct oral anticoagulant reversal, thrombocytosis, and antiphospholipid antibody syndromes. Treatment options for managing patients with heparin resistance include weight-based dosing and administration of additional UFH, antithrombin supplementation, or the use of an alternative anticoagulant such as the direct thrombin inhibitors bivalirudin or argatroban.<\/jats:p>","DOI":"10.1182\/hematology.2024000659","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T10:01:29Z","timestamp":1733479289000},"page":"186-191","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Troubleshooting heparin resistance"],"prefix":"10.1182","volume":"2024","author":[{"given":"Cheryl L.","family":"Maier","sequence":"first","affiliation":[{"name":"1 Department of Pathology and Laboratory Medicine, Emory School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"2 Department of Medicine, Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold H.","family":"Levy","sequence":"additional","affiliation":[{"name":"3 Departments of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"9","key":"2024121115351601300_hem2024000659C1","article-title":"Coagulation time of blood heparinized in vitro: correlation of results with those of the heparin tolerance test","volume":"32","author":"Hagedorn","year":"1947","journal-title":"J Lab Clin Med"},{"issue":"1","key":"2024121115351601300_hem2024000659C2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Intern Med"},{"issue":"12","key":"2024121115351601300_hem2024000659C3","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/j.jtha.2023.08.013","article-title":"Defining heparin resistance: communication from the ISTH SSC subcommittee of perioperative and critical care thrombosis and hemostasis","volume":"21","author":"Levy","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"2 suppl","key":"2024121115351601300_hem2024000659C4","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"issue":"6","key":"2024121115351601300_hem2024000659C5","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1021\/acs.chemrev.1c00118","article-title":"Introduction: drug resistance","volume":"121","author":"Kurt Yilmaz","year":"2021","journal-title":"Chem Rev"},{"issue":"6","key":"2024121115351601300_hem2024000659C6","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00246-004-0919-7","article-title":"Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia","volume":"26","author":"Yilmaz","year":"2005","journal-title":"Pediatr Cardiol"},{"issue":"9","key":"2024121115351601300_hem2024000659C7","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMra2104091","article-title":"Heparin resistance - clinical perspectives and management strategies","volume":"385","author":"Levy","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2024121115351601300_hem2024000659C8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"6","key":"2024121115351601300_hem2024000659C9","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"6","key":"2024121115351601300_hem2024000659C10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/00185787221111743","article-title":"Heparin resistance in SARS- CoV-2 infected patients with venous thromboembolism","volume":"57","author":"Chau","year":"2022","journal-title":"Hosp Pharm"},{"issue":"2","key":"2024121115351601300_hem2024000659C11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jtcvs.2003.12.023","article-title":"Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?","volume":"128","author":"Teoh","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"2024121115351601300_hem2024000659C12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"6","key":"2024121115351601300_hem2024000659C13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1213\/ANE.0b013e3182662e1a","article-title":"A case series of recombinant platelet factor 4 for heparin reversal after cardiopulmonary bypass","volume":"115","author":"Demma","year":"2012","journal-title":"Anesth Analg"},{"issue":"4","key":"2024121115351601300_hem2024000659C14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1309\/AJCPS6OW6DYNOGNH","article-title":"Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance","volume":"139","author":"Takemoto","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"04","key":"2024121115351601300_hem2024000659C15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1160\/TH15-08-0687","article-title":"Antithrombin: anti-inflammatory properties and clinical applications","volume":"115","author":"Levy","year":"2016","journal-title":"Thromb Haemost"},{"key":"2024121115351601300_hem2024000659C16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00134-022-06723-z","article-title":"How to manage anticoagulation during extracorporeal membrane oxygenation","volume":"48","author":"Levy","year":"2022","journal-title":"Intensive Care Med"},{"issue":"1","key":"2024121115351601300_hem2024000659C17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.jvca.2020.09.091","article-title":"Andexanet alfa use in cardiac surgical patients: a Xa Inhibitor and Heparin Reversal Agent","volume":"35","author":"Levy","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"6","key":"2024121115351601300_hem2024000659C18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jtha.2024.02.013","article-title":"Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?","volume":"22","author":"Iba","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2024121115351601300_hem2024000659C19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00134-023-07103-x","article-title":"Resistance to unfractionated heparin in the ICU: evaluation and management options","volume":"49","author":"Levy","year":"2023","journal-title":"Intensive Care Med"},{"issue":"4","key":"2024121115351601300_hem2024000659C20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/jcm9040963","article-title":"A prospective pilot trial to assess the efficacy of argatroban (Argatra(\u00ae)) in critically ill patients with heparin resistance","volume":"9","author":"Bachler","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"2024121115351601300_hem2024000659C21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/MAT.0000000000001808","article-title":"Heparin versus bivalirudin for anticoagulation in adult extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"69","author":"Wieruszewski","year":"2023","journal-title":"ASAIO J"},{"issue":"2","key":"2024121115351601300_hem2024000659C22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0000000000004814","article-title":"Monitoring argatroban anticoagulation in the critically ill: all tests are not created equal","volume":"140","author":"Erdoes","year":"2024","journal-title":"Anesthesiology"},{"issue":"2","key":"2024121115351601300_hem2024000659C23","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/ALN.0000000000001976","article-title":"Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery","volume":"128","author":"Koster","year":"2018","journal-title":"Anesthesiology"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/186\/2346435\/186maier.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/186\/2346435\/186maier.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T12:00:16Z","timestamp":1733918416000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/186\/526159\/Troubleshooting-heparin-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000659","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}